Clinical Evaluation of Leukotriene Receptor Antagonists in Preventing Common Cold-like Symptoms in Bronchial Asthma Patients

Horiguchi, T.; Ohira, Daisuke; Kobayashi, Kashin; Hirose, Masahiro; Miyazaki, Junichi; Kondo, Rieko; Tachikawa, Soichi

doi:10.2332/allergolint.o-06-473

Cited by 8 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with the present study, LTRA treatment was associated with a lower incidence of common cold-like symptoms in a retrospective analysis of adult asthma. 21 However, contrary to the present results, Kozer et al reported that montelukast did not reduce the incidence or duration of URI in preschool-aged children who did not have asthma. 22 Thus, LTRA treatment may only be effective for asthmatic patients, who have higher LT levels in the airway while stable, to prevent URI symptoms.…”

Section: Discussioncontrasting

confidence: 99%

Retrospective Cohort Study of Leukotriene Receptor Antagonist Therapy for Preventing Upper Respiratory Infection-Induced Acute Asthma Exacerbations

Matsuse

Tsuchida

Fukahori

et al. 2013

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

Upper respiratory tract infections (URIs) represent the most frequent cause of acute asthma exacerbations. It has yet to be determined whether leukotriene receptor antagonist (LTRA) treatment prevents URI-induced acute asthma exacerbations in adults. The objective of the present study was to evaluate the preventive effects of LTRA treatment on URI-induced acute asthma exacerbations. The incidences of URI alone, acute asthma exacerbation without URI, and URI-induced acute asthma exacerbation were determined retrospectively by analyzing diary and medical records of 321 adult asthmatic patients (mean age, 56.3 ± 17.2 years; male/female ratio, 117:204) over 1 year. Results were compared between patients who had been taking an LTRA (n = 137) and those who had never taken any LTRA (n = 184) during the study periods. Significantly fewer URIs alone and acute asthma exacerbations without URI occurred in patients with than in those without prophylactic daily use of LTRA. LTRA treatment significantly reduced the durations of URIs alone and of total acute asthma exacerbations, as well as the incidence of mild exacerbations of asthma. In contrast, in patients with URI-induced acute asthma exacerbations, LTRA treatment failed to significantly reduce the interval between URI onset and acute asthma exacerbation, as well as the duration and severity of both URIs and acute asthma exacerbations. Use of an LTRA for adult asthmatic patients appears to reduce the incidences of URIs alone and acute asthma exacerbations without URI, but it failed to prevent URI-induced acute asthma exacerbations once a URI occurred.

show abstract

Section: Discussioncontrasting

confidence: 99%

Retrospective Cohort Study of Leukotriene Receptor Antagonist Therapy for Preventing Upper Respiratory Infection-Induced Acute Asthma Exacerbations

Matsuse

Tsuchida

Fukahori

et al. 2013

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

show abstract

“…LTs play a pivotal role in the acute phase of respiratory conditions such as (i) asthma, (ii) viral pneumonia, (iii) acute lung injury (ALI), (iv) systemic inflammatory response syndrome (SIRS), (v) ARDS, and (vi) pulmonary fibrosis (Beller et al, 2004;Caironi et al, 2005;Horiguchi et al, 2007;Okunishi and Peters-Golden, 2011;Al-Amran et al, 2013). LTs mediate various molecular and cellular pathologies in respiratory disease, and LT inhibition alleviates respiratory pathology (Sorkness, 1997;McMillan, 2001;Scott and Peters-Golden, 2013).…”

Section: Cysteinyl Leukotrienes In Lung and Respiratory Disease Pathomentioning

confidence: 99%

The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic

Aigner

Pietrantonio²,

Sousa

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

The emergence and global impact of COVID-19 has focused the scientific and medical community on the pivotal influential role of respiratory viruses as causes of severe pneumonia, on the understanding of the underlying pathomechanisms, and on potential treatment for COVID-19. The latter concentrates on four different strategies: (i) antiviral treatments to limit the entry of the virus into the cell and its propagation, (ii) anti-inflammatory treatment to reduce the impact of COVID-19 associated inflammation and cytokine storm, (iii) treatment using cardiovascular medication to reduce COVID-19 associated thrombosis and vascular damage, and (iv) treatment to reduce the COVID-19 associated lung injury. Ideally, effective COVID-19 treatment should target as many of these mechanisms as possible arguing for the search of common denominators as potential drug targets. Leukotrienes and their receptors qualify as such targets: they are lipid mediators of inflammation and tissue damage and well-established targets in respiratory diseases like asthma. Besides their role in inflammation, they are involved in various other aspects of lung pathologies like vascular damage, thrombosis, and fibrotic response, in brain and retinal damages, and in cardiovascular disease. In consequence, leukotriene receptor antagonists might be potential candidates for COVID-19 therapeutics. This review summarizes the current knowledge on the potential involvement of leukotrienes in COVID-19, and the rational for the use of the leukotriene receptor antagonist montelukast as a COVID-19 therapeutic.

show abstract

“…It has been reported that levels of sulfidopeptide leukotrienes are increased during infections with RSV, influenza, or HRV (Volovitz et al, 1988;Gentile et al, 2003), although data for the latter virus remain controversial. Several studies have reported that the use of leukotriene receptor antagonists, normally added on as a second-line treatment to usual ICS therapy, reduced asthma symptoms or exacerbations due to colds in children Horiguchi et al, 2007;Johnston et al, 2007;Robertson et al, 2007). By contrast, in children with RSV bronchiolitis, the use of montelukast did not reduce symptoms, nor did it significantly effect the number, or time to onset, of subsequent exacerbations (Bisgaard et al, 2008;Proesmans et al, 2009).…”

Section: Leukotriene Receptor Antagonists and Bronchodilatorsmentioning

confidence: 99%

Virus-induced modulation of lower airway diseases: Pathogenesis and pharmacologic approaches to treatment

Leigh

Proud

2015

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Uncomplicated upper respiratory viral infections are the most common cause of days lost from work and school and exert a major economic burden. In susceptible individuals, however, common respiratory viruses, particularly human rhinoviruses, also can have a major impact on diseases that involve the lower airways, including asthma, chronic obstructive pulmonary diseases (COPD) and cystic fibrosis (CF). Respiratory virus-induced wheezing illnesses in early life are a significant risk factor for the subsequent development of asthma, and virus infections may also play a role in the development and progression of airway remodeling in asthma. It is clear that upper respiratory tract virus infections can spread to the lower airway and trigger acute attacks of asthma, COPD or CF. These exacerbations can be life-threatening, and exert an enormous burden on health care systems. In recent years we have gained new insights into the mechanisms by which respiratory viruses may induce acute exacerbations of lower airway diseases, as well as into host defense pathways that may regulate the outcomes to viral infections. In the current article we review the role of viruses in lower airway diseases, including our current understanding on pathways by which they may cause remodeling and trigger acute exacerbations. We also review the efficacy of current and emerging therapies used to treat these lower airway diseases on the outcomes due to viral infection, and discuss alternative therapeutic approaches for the management of virus-induced airway inflammation.

show abstract

Clinical Evaluation of Leukotriene Receptor Antagonists in Preventing Common Cold-like Symptoms in Bronchial Asthma Patients

Cited by 8 publications

References 18 publications

Retrospective Cohort Study of Leukotriene Receptor Antagonist Therapy for Preventing Upper Respiratory Infection-Induced Acute Asthma Exacerbations

Retrospective Cohort Study of Leukotriene Receptor Antagonist Therapy for Preventing Upper Respiratory Infection-Induced Acute Asthma Exacerbations

The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic

Virus-induced modulation of lower airway diseases: Pathogenesis and pharmacologic approaches to treatment

Contact Info

Product

Resources

About